Literature DB >> 31939529

Chronic Kidney Disease.

Adriano Luiz Ammirati1,2.   

Abstract

Chronic kidney disease is highly prevalent (10-13% of the population), irreversible, progressive, and associated with higher cardiovascular risk. Patients with this pathology remain asymptomatic most of the time, presenting the complications typical of renal dysfunction only in more advanced stages. Its treatment can be conservative (patients without indication for dialysis, usually those with glomerular filtration rate above 15 ml/minute) or replacement therapy (hemodialysis, peritoneal dialysis, and kidney transplantation). The objectives of the conservative treatment for chronic kidney disease are to slow down the progression of kidney dysfunction, treat complications (anemia, bone diseases, cardiovascular diseases), vaccination for hepatitis B, and preparation for kidney replacement therapy.

Entities:  

Mesh:

Year:  2020        PMID: 31939529     DOI: 10.1590/1806-9282.66.S1.3

Source DB:  PubMed          Journal:  Rev Assoc Med Bras (1992)        ISSN: 0104-4230            Impact factor:   1.209


  29 in total

1.  [Triglyceride-glucose product is an independent risk factor for predicting chronic kidney disease in middle-aged and elderly population: a prospective cohort study].

Authors:  X Xu; X Tang; H Che; C Guan; N Zhao; S Fu; L Liu; Y Ye; M Guo; H Min; D Zhen
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-11-20

2.  Identification of circulating lncRNA in chronic kidney disease based on bioinformatics analysis.

Authors:  Rong Huang; Li-Jing Sun
Journal:  Exp Biol Med (Maywood)       Date:  2022-06-25

3.  Baicalin Attenuates Continuous Activation of β-Catenin Induced by Lipopolysaccharide (LPS) and Depression Complicated by Infertility in Male Rats.

Authors:  Rong Fan; Feng Dai; Chunhu Zhang; Lu Zhou; Xinjian Qiu; Yunhui Li
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-07       Impact factor: 2.650

4.  Association of Air Pollutants with Incident Chronic Kidney Disease in a Nationally Representative Cohort of Korean Adults.

Authors:  Seo Yun Hwang; Seogsong Jeong; Seulggie Choi; Dong Hyun Kim; Seong Rae Kim; Gyeongsil Lee; Joung Sik Son; Sang Min Park
Journal:  Int J Environ Res Public Health       Date:  2021-04-04       Impact factor: 3.390

5.  Circulating miRNA-29b and Sclerostin Levels Correlate with Coronary Artery Calcification and Cardiovascular Events in Maintenance Hemodialysis Patients.

Authors:  Jiqing He; Mingjiao Pan; Mingzhi Xu; Ruman Chen
Journal:  Cardiol Res Pract       Date:  2021-12-23       Impact factor: 1.866

6.  Farnesylthiosalicylic Acid-Loaded Albumin Nanoparticle Alleviates Renal Fibrosis by Inhibiting Ras/Raf1/p38 Signaling Pathway.

Authors:  Hui Huang; Qinhui Liu; Ting Zhang; Jinhang Zhang; Jian Zhou; Xiandan Jing; Qin Tang; Cuiyuan Huang; Zijing Zhang; Yingnan Zhao; Guorong Zhang; Jiamin Yan; Yan Xia; Ying Xu; Jiahui Li; Yanping Li; Jinhan He
Journal:  Int J Nanomedicine       Date:  2021-09-21

7.  Blood Glucose and Renal Function Evaluation in Patients with Viral Hepatitis.

Authors:  Wen-Tung Hsu; Deng-Ho Yang; Chun-Cheng Liao; Jia-Wen Chen; Wen-Hsiu Hsu; Chia-Wen Kuo; Hung-Chang Hsu; Sheng-Huang Chang; Li-Mien Chen
Journal:  Diabetes Metab Syndr Obes       Date:  2021-07-20       Impact factor: 3.168

Review 8.  Exosomes and Melatonin: Where Their Destinies Intersect.

Authors:  Adriana Alonso Novais; Luiz Gustavo de Almeida Chuffa; Débora Aparecida Pires de Campos Zuccari; Russel J Reiter
Journal:  Front Immunol       Date:  2021-06-11       Impact factor: 7.561

9.  Mesenchymal Stem Cells Attenuate Renal Fibrosis via Exosomes-Mediated Delivery of microRNA Let-7i-5p Antagomir.

Authors:  Juan Jin; Fengmei Qian; Danna Zheng; Wenfang He; Jianguang Gong; Qiang He
Journal:  Int J Nanomedicine       Date:  2021-05-25

Review 10.  Interleukin-33/ Suppression of Tumorigenicity 2 in Renal Fibrosis: Emerging Roles in Prognosis and Treatment.

Authors:  Xiao-Yang Tan; Hao-Yue Jing; Yue-Rong Ma
Journal:  Front Physiol       Date:  2022-01-03       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.